MK-1084 | MedChemExpress (MCE)
MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits anticancer activity and can be used either alone or in combination with pembrolizumab (HY-P9902) for cancer research[1].
| Trivial name | MK-1084 |
| Catalog Number | HY-162431 |
| Research Area | Cancer |
| CAS# | 2641216-67-1 |
| Purity | ≥98.0% |
| SMILES | FC1=C2C(OCCOC3=CC=NC(C(C)C)=C3N4C5=NC2=C(Cl)C=C5C(N6[C@@H](C)CN(C(C=C)=O)[C@H](C)C6)=NC4=O)=C(F)C=C1 |
| Size | 1 mg |
| Supplier Page | https://www.medchemexpress.com/mk-1084.html |